Do probiotics prevent C. difficile infection?
Moderate EvidenceIT DEPENDS
Multiple meta-analyses suggest probiotics reduce C. difficile infection risk by 50-60% when co-administered with antibiotics. However, the largest pragmatic trial (PLACIDE) found no benefit in elderly hospitalized patients, raising questions about generalizability.
The Verdict
Multiple meta-analyses suggest probiotics reduce C. difficile infection risk by 50-60% when co-administered with antibiotics. However, the largest pragmatic trial (PLACIDE) found no benefit in elderly hospitalized patients, raising questions about generalizability.
What the Evidence Shows
Clostridioides difficile infection (CDI) is a serious complication of antibiotic use, and probiotics have been extensively studied as a preventive strategy. Goldenberg et al. (2017) conducted a Cochrane review of 31 randomized trials (8,672 participants) finding that probiotics significantly reduced CDI risk by 60% (RR 0.40, 95% CI 0.30-0.52). The absolute risk reduction was most meaningful in high-risk populations (baseline CDI rate >5%). Shen et al. (2017) performed a meta-analysis focused on moderate-to-high quality studies and found similar protective effects, with a number needed to treat of approximately 43 patients to prevent one CDI episode. Johnston et al. (2012) published a meta-analysis in the Annals of Internal Medicine confirming that probiotics reduced the incidence of C. difficile-associated diarrhea by 66% in hospitalized patients receiving antibiotics. However, the PLACIDE trial (Allen et al., 2013) was a large pragmatic RCT of 2,981 hospitalized patients aged 65+ receiving antibiotics, which found absolutely no benefit of a multistrain Lactobacillus and Bifidobacterium preparation for CDI prevention (RR 1.04, 95% CI 0.84-1.28). This trial is particularly important because its pragmatic design more closely reflects real-world clinical conditions than the smaller efficacy trials. The discrepancy may relate to probiotic strain specificity, timing of administration, patient population differences, or baseline CDI risk levels. Current guidelines suggest probiotics may be considered in high-risk populations but are not universally recommended.
Evidence Quality
4
Meta-Analyses
31
RCTs
5
Observational
Important Caveats
- ⚠️ The largest pragmatic trial (PLACIDE, n=2981) showed no benefit whatsoever
- ⚠️ Probiotic strain, dose, and timing vary widely across positive studies
- ⚠️ Benefits may only apply to high-baseline-risk populations (>5% CDI rate)
- ⚠️ Small positive trials may be subject to publication bias
- ⚠️ Safety concerns exist for immunocompromised or critically ill patients
Population Studied
Hospitalized adults receiving systemic antibiotics; PLACIDE focused on elderly (65+); meta-analyses include broader adult populations in hospital settings
Dosage
Varies by study: Lactobacillus rhamnosus GG, Saccharomyces boulardii, or multi-strain preparations; typically 10^9-10^10 CFU daily; started within 48h of antibiotic initiation
Duration
Typically co-administered for duration of antibiotic course plus 5-14 days; outcomes measured up to 4-6 weeks post-antibiotic
Supporting Studies (3)
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Meta-AnalysisGoldenberg JZ, Yap C, Lytvyn L, et al. · Cochrane Database of Systematic Reviews (2017)
Cochrane review of 31 RCTs (8,672 participants) found that probiotics reduced CDI risk by 60% (RR 0.40). The benefit was most meaningful in populations with high baseline CDI risk (>5%), with a number needed to treat of 12 in high-risk groups.
View paper (DOI) →Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis
Meta-AnalysisShen NT, Maw A, Tmanova LL, et al. · Gastroenterology (2017)
Meta-analysis found probiotics significantly reduced CDI when started within 2 days of antibiotic initiation (RR 0.32), but not when started later, suggesting timing is critical for effectiveness.
View paper (DOI) →Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis
Meta-AnalysisJohnston BC, Ma SSY, Goldenberg JZ, et al. · Annals of Internal Medicine (2012)
Meta-analysis of 20 RCTs (3,818 participants) found that probiotics reduced CDI incidence by 66% (RR 0.34, 95% CI 0.24-0.49) in hospitalized patients receiving antibiotics.
View paper (DOI) →Contradicting Studies (1)
Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial
RCTAllen SJ, Wareham K, Wang D, et al. · The Lancet (2013)
Large pragmatic RCT of 2,981 hospitalized patients aged 65+ found no benefit of a multi-strain Lactobacillus/Bifidobacterium preparation for preventing CDI (RR 1.04) or antibiotic-associated diarrhea compared to placebo.
Why this disagrees:
As the largest and most pragmatic trial, PLACIDE found zero benefit despite adequate power and real-world conditions. This suggests the positive results from smaller trials may not generalize to typical clinical practice, or that the specific strains and patient population in PLACIDE differed critically from conditions in positive studies.
Related Claims
Does high fiber intake reduce type 2 diabetes risk?
Strong EvidenceStrong evidence from large prospective studies and meta-analyses consistently demonstrates that higher dietary fiber intake is associated with significantly reduced type 2 diabetes risk. The relationship is dose-dependent and most robust for cereal fiber and whole grain consumption.
Does magnesium supplementation improve depression symptoms?
Moderate EvidencePreliminary evidence from a small number of trials suggests magnesium supplementation may improve mild-to-moderate depression symptoms, particularly in those with low magnesium intake. However, the evidence base is small, and observational study limitations complicate interpretation.
Does omega-3 supplementation reduce triglycerides?
Strong EvidenceStrong evidence confirms that omega-3 fatty acid supplementation (EPA and DHA) reduces triglyceride levels by 20-30% at prescription doses, with dose-dependent effects. This is one of the most well-established supplement effects. However, triglyceride reduction does not consistently translate to reduced cardiovascular events.